Abacavir/Lamivudine Fixed-Dose Combination Tablet for the Treatment of HIV-1 Infection

• Gottlieb MS , SchroffR, SchankerHMet al.: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.N. Engl. J. Med.305(24), 1425–1431 (1981).
   PubMed Web of Science ®Google Scholar
• Hymes KB , CheungT, GreeneJBet al.: Kaposis sarcoma in homosexual men – a report of eight cases.Lancet2(8247), 598–600 (1981).
   PubMed Web of Science ®Google Scholar
• Tassie JM , GrabarS, LancarR, DeloumeauxJ, BentataM, CostagliolaD: Time to AIDS from 1992 to 1999 in HIV-1 infected subjects with known dates of infection.J. AIDS30(1), 81–87 (2002).
   PubMed Web of Science ®Google Scholar
• Chesney MA : Factors affecting adherence to antiretroviral therapy.CID30(Suppl. 2), S171–S176 (2000).
   PubMed Web of Science ®Google Scholar
• Gazzard B : BHIVA writing committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.HIV Med.6(Suppl. 2), 1–61 (2005).
   PubMed Web of Science ®Google Scholar
• Hammer SM , SaagMS, SchechterMet al.: Treatment for Adult HIV Infection. 2006 Recommendations of the International AIDS Society – USA panel.JAMA296(7), 296–243 (2006).
   Web of Science ®Google Scholar
• Maitland D , MoyleG, HandJet al.: Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.AIDS19(11), 1183–1188 (2005).
   PubMed Web of Science ®Google Scholar
• Baker KL , LouY, YuenGJ, MurrayS, SteinD: The bioequivalence and effect of foos of a new once-aday fixed dose combination tablet of abacavir (ABC) and lamivudine (3TC). Abstract A-458. Presented at: 44th Annual ICAAC.Washington DC, USA, 30October–2 November (2004).
   Google Scholar
• Caparelli EV , LetendreSL, EllisRJ, PatelP, HollandD, McCutchanJA: Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid.Antimicrob. Agents Chemother.49(6), 2504–2506 (2005).
   PubMed Web of Science ®Google Scholar
• Girard PM , KatlamaC, PialouxG: VIH 6th edition (2004).
   Google Scholar
• Bergshoeff A , BurgerD, VerweijCet al.: PENTA-13 study group. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1 infected children (PENTA-13).Antivir. Ther.10(2), 239–246 (2005).
   PubMed Web of Science ®Google Scholar
• Bruce RD , AlticeFL, GourevitchMN, FriedlandGH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice.J. Acquir. Immune Defic. Syndr.41, 563–572 (2006).
   PubMed Web of Science ®Google Scholar
• Sellers E , LamR, McDowellJet al.: The pharmacokinetics (pk) of abacavir (ABC) and methadone (M) following co-administration: CNAA1012 (abstract 663]. Presented at: 39th Interscience Conference on Antimicrobials Agents and Chemotherapy.San Francisco, USA, 26–29September (1999).
   Google Scholar
• Moyle G : Resistance and cross resistance to abacavir.HIV Med.2, 154–162 (2001).
   PubMedGoogle Scholar
• Harrigan PR , StoneC, GriffinPet al.: Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.J. Infect. Dis.181, 912–920 (2000).
   PubMed Web of Science ®Google Scholar
• DeJesus E , HerreraG, TeofiloEet al.: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults.Clin. Infect. Dis.39, 1038–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Moyle GJ , DeJesusE, CahnP, CastilloSA, ZhaoH, GordonDN: Abacavir once or twice daily combined with once daily lamivudine and efavirenz for the treatment of antiretroviral naïve HIV-infected adults: results of the Ziagen once daily in antiretroiviral combination study.J. AIDS38(4), 417–425 (2005).
   PubMed Web of Science ®Google Scholar
• Bartlett JA , JohnsonJ, HerreraGet al.: Long term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir or stavudine.J. Acquir. Immune Defic. Syndr. (2006) (Epub ahead of print).
   Web of Science ®Google Scholar
• Podzamcer D , FerrerE, SánchezPet al.: A randomized comparison of abacavir and stavudine, combined with lamivudine/efavirenz, in antiretroviral-naive patients. Final 96-week results (ABCDE study). Presented at: 12th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA, 22–25February (2005) (Abstract 587).
   Google Scholar
• Rodriguez-French A , BoghossianJ, GrayGEet al.: The NEAT Study: A 48 week open-label study to compare the antiviral efficacy and safety of GW433908 versus Nelfinavir in antiretroviral therapy-naïve HIV-1 Infected Patients.J. AIDS35(1), 22–32 (2004).
   PubMed Web of Science ®Google Scholar
• Gathe J , IveP, WoodRet al.: SOLO: 48 week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice daily nelfinavir in naïve HIV-1-infected patients.AIDS18, 1529–1537 (2004).
   PubMed Web of Science ®Google Scholar
• Gathe J , WoodR, SanneI, DeJesusE, SchurmannD, GladyszAet al.: Long term (120 week) antiviral efficacy of fosamprenavir/ritonavir once daily in therapy naïve patients with HIV infection: an uncontrolled, open label, single arm follow on study.Clin. Ther.28(5), 745–754 (2006).
   PubMed Web of Science ®Google Scholar
• Eron J , YeniP, GatheJet al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.Lancet368, 476–482 (2006).
   PubMed Web of Science ®Google Scholar
• Sosa N , Hill-ZabalaC, DeJesusEet al.: Abacavir and Lamivudine fixed dose combination once daily compared with abacavir and lamivudine twice daily in HIV infected patients over 48 weeks.J. AIDS40(4), 422–427 (2005).
   PubMed Web of Science ®Google Scholar
• Lamarca A , ClumeckN, PlattenbergAet al.: Efficacy and safety of a once daily fixed dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral experienced HIV-1 infected patients (CAL30001 study)J. Acquir. Immune Defic. Syndr.41(5), 598–606 (2006).
   PubMed Web of Science ®Google Scholar
• Gallant JE , RodriguezAE, WeinbergWGet al.: Early virologic nonresponse to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naive subjects.J. Infect. Dis.192(1), 1921–1930 (2005).
   PubMedGoogle Scholar
• Landman R , PeytavinG, DescampsDet al.: Low genetic barrier to resistance is a possible cause if early virologic failures in once daily regimen of abacavir, lamivudine and tenofovir: The Tonus study.HIV Clin. Trials6(6), 291–301 (2005).
   PubMed Web of Science ®Google Scholar
• Paediatric European Network for Treatment of AIDS. Comparison of dual nucleoside analogue reverse transcriptase inhibitor regimes with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomized trial. Lancet 359, 733–740 (2002).
   PubMed Web of Science ®Google Scholar
• Mocroft A , DevereuxH, Kinloch-de-LoesSet al.: Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimes in complete clinic populations.AIDS14, 1545–1552 (2000).
   PubMed Web of Science ®Google Scholar
• Shlay JC , VisnegarwalaF, BartschGet al.: Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine versus abacavir and lamivudine.J. AIDS38(2), 147–155 (2005).
   PubMed Web of Science ®Google Scholar
• Moyle G , BaldwinC, LangroudiB, MandaliaS, GazzardBG: A 48-week randomized open-label comparison of three abacavir-based substitution approaches in the management of dyslipidaemia and peripheral lipoatrophy.J. AIDS33(1), 22–28 (2003).
   PubMed Web of Science ®Google Scholar
• Martin A , SmithDE, CarrAet al.: Reversibility of lipoatrophy in HIV infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study.AIDS18(7), 1029–1036 (2005).
   Web of Science ®Google Scholar
• GlaxoSmithKline Kivexa™ (abacavir & lamivudine) Product Monograph (2004).
   Google Scholar
• Hetherington S , McGuirkS, PowellGet al.: Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.Clin. Ther.23, 1603–1614 (2001).
   PubMed Web of Science ®Google Scholar
• Steckler J , MaenzaJ, StevensCet al.: Abacavir hypersensitivity reaction in primary HIV infection.AIDS20(9), 1269–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Nolan D , GauderiS, MallalS: Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?J. HIV Ther.8(2), 6–41 (2003).
   Google Scholar
• Mallal S , NolanD, WittCet al.: Association between presence of HLA-B5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir.Lancet359, 727–732 (2002).
   PubMed Web of Science ®Google Scholar
• Reeves I , ChurchillD, FisherM: Clinical Utility of HLA-B*5701 testing in a UK clinic cohort.HIV Med.7(Suppl. 1), 5 (2006) (Abstract no 019).
   Google Scholar
• Bowonwatanuwong C , WarrenL, MostellerMet al.: Association of HLA-B*5701 and hypersensitivity to abacavir in a sample of Thai patients.Antivir. Ther.3, 61 (2005).
   Google Scholar
• Hetherington S , HughesAR, MostellerMet al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.Lancet359(9312), 1121–1122 (2002).
   PubMed Web of Science ®Google Scholar
• Phillips EJ , SullivanJR, KnowlesSR, ShearNH: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.AIDS16(16), 2223–2225 (2002).
   PubMed Web of Science ®Google Scholar
• Phillips EJ , WongGA, KaulRet al.: Clinical and immunogenetic correlates of abacavir hypersensitivity.AIDS119(9), 979–981 (2005).
   Google Scholar
• Rauch A , NolanD, MartinA, McKinnonE, AlmeidaC, MallalS: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reaction in the Western Australian HIV cohort study.CID43(1), 99–102 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• World Health Organisation. WHO AIDS epidemic update 2005 www.who.int/hiv/epi-update2005_en.pdf
   Google Scholar
• British HIV Association (BHIVA)/British Association for Sexual Health and HIV (BASHH) guidelines on provision of adherence support to individuals receiving antiretroviral therapy (2003) www.bhiva.org/guidelines/2004/adherence/index.html
   Google Scholar
• EACS Euroguidelines Group. European guidelines for the clinical managemene and treatment of HIV infected adults in Europe (2005) www.eacs.ws/download/euroguidelines4151105.pdf
   Google Scholar
• Summary of product characteristics: Kivexa. GlaxoSmithKline (2004) www.medicines.org.uk
   Google Scholar
• GlaxoSmithKline. www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=384
   Google Scholar
• US Food and Drug Administration www.fda.gov/bbs/topics/news/2004/NEW01099.html
   Google Scholar
• World Health Organisation HIV/AIDS programme. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. Recommendations for a public health approach (2006). www.who.int/hiv/pub/guidelines/art/en/ index.html
   Google Scholar